# A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

> **NCT05083949** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** FDC 12.5mg empagliflozin/850mg metformin
- **DRUG:** Empagliflozin
- **DRUG:** Glifage®

## Key facts

- **NCT ID:** NCT05083949
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-23
- **Primary completion:** 2021-08-06
- **Final completion:** 2021-09-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083949, "A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05083949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*